Campylobacter, Salmonella, Shigella and Yersinia were most frequently included in the stool tests, and Campylobacter was detected most often in patients (14%).
The aim of this study is to assess the clinical impact of diagnostic stool testing in critically ill patients.
Use of antibiotics in the previous six months is cause for rejection, as is travel to the developing world and the presence in a stool test of pathogens like B. hominis, a parasite that is found in up to ten per cent of healthy people.
Campylobacter (requested for 87% of the tests), Salmonella (84%), Shigella (78%) and Yersinia (56%) were most frequently included in the stool tests.
However, in low-resource countries like Ghana stool testing for etiologic diagnosis of diarrhea is not routinely done in practice.
We were unable to identify any recent change in stool-testing procedures, products, or handling that would have explained an outbreak this year, in comparison with prior years, when similar methods were presumably used.
We evaluated data from gastroenteritis outbreaks in Oregon to assess sensitivity of stool testing for norovirus and determine number of specimens needed to confirm norovirus as the cause.
Subjects who do not participate in stool DNA testing, those with false negative results and those who refuse diagnostic colonoscopy will return to the disease natural history.
An increase in stool antigen testing for Campylobacter spp. would affect surveillance data by causing the number of cases to be underestimated because of poor testing sensitivity and may also result in hampering outbreak investigation because of the poor specificity of antigen testing.
The U.S. Preventive Services Task Force, a government-backed agency, recommends screening for people age 50 to 75 years by one of three methods: a colonoscopy every 10 years; annual stool testing; or a less-thorough look into the colon (known as flexible sigmoidoscopy) every five years in conjunction with stool testing every two to three years.
